177Lu-PSMA-617 (trade name: Pluvicto) is a radiopharmaceutical used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This drug is a peptide radiopharmaceutical that combines a PSMA-targeting ligand with the radioisotope lutetium-177, delivering radiation therapy by binding to PSMA-positive cancer cells.
177Lu-PSMA-617 (trade name: Pluvicto) is a radiopharmaceutical used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This drug is a peptide radiopharmaceutical that combines a PSMA-targeting ligand and a radioisotope, Lutetium-177, to deliver radiotherapy by binding to PSMA-positive cancer cells.
PSMA is a protein that is overexpressed on the surface of prostate cancer cells, making it an ideal target for radiotherapy. Lutetium (177Lu) Vipivotide Tetraxetan binds to PSMA with high affinity, delivering the radioisotope directly to cancer cells, thereby reducing damage to surrounding normal tissue.
